Last updated: 2026-09-09 05:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
NeoGenomics, Inc. (NEO) operates in the SERVICES-TESTING LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $17.57, with a market capitalization of $2.23B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.07 to $19.76. This page covers its latest market performance, valuation, price trends and company information.
$2.23B | |
$17.15 | |
$61.57 | |
$2.05 | |
$17.38 | |
953.50K | |
2.85M | |
-- | |
$19.76 | |
$7.07 | |
-- | |
-- |
NeoGenomics, Inc. (NEO) last closed at $17.38 as of 2026-09-08 23:58:00, unchanged from the previous close of $17.38.
During the latest regular trading session, NEO traded between $2.05 and $61.57, with a volume of 953.50K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, NeoGenomics, Inc. (NEO) moved from $18.64 to $17.57, representing a decline of 5.75% ($1.07).
The stock traded between $16.87 and $19.76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.11 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 82.7%
NEO is currently trading at $17.57, placing it 82.7% of the way from its 52-week low of $7.07 to its 52-week high of $19.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
| Industry | SERVICES-TESTING LABORATORIES |
| Employees | 2500 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeoGenomics, Inc. (NEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.